Skip to main content
. 2014 Dec 10;6(2):995–1007. doi: 10.18632/oncotarget.2739

Figure 3. Inhibition of downstream signaling and CCR7 promoter by TAK1 inhibitor.

Figure 3

(A) MDA-MB-231 cells were treated with different doses of 5Z-O for 24 h. The kinase activity of p38, JNK and IKK was assayed by using phosphor-specific antibodies. (B) Scheme of the CCR7 promoter-luciferase plasmids P1, P2 and P3 used in reporter assays. (C) P1 plasmid was transfected into MDA-MB-231 cells by using Lipofectamine reagent. After transfection, cells were treated with vehicle (0.1% DMSO) or various concentrations of 5Z-O in 10% FCS medium for 24 h and luciferase activity was determined. The luciferase activity of the control group was defined as 1. *p < 0.05. (D) MDA-MB-231 cells were transfected with P1, P2 or P3 vectors and were incubated without or with 5Z-O for 24 h. Luciferase activity was measured and the difference between different experimental groups was compared. *p < 0.05.